Verve Therapeutics, Inc. (VERV)
| Market Cap | 2.15B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 7.95M |
| EPS (ttm) | -25.50 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 70,126 |
| Open | 44.66 |
| Previous Close | 44.81 |
| Day's Range | 44.14 - 45.80 |
| 52-Week Range | 29.50 - 78.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings Date | Nov 11, 2021 |
About VERV
Verve Therapeutics is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, or CVD, transforming treatment from chronic management to single-course gene editing medicines. The current paradigm of chronic care is fragile – requiring rigorous patient adherence, extensive healthcare infrastructure and regular healthcare access – and leaves many patients without adequate care. Our goal is to disrupt the chronic care model for CVD by providing a new therapeutic approach with single-course in vivo gene editi...
Financial Performance
Financial StatementsNews
Verve Therapeutics to Participate in the Jefferies Gene Therapy/Editing Summit
CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Verve Therapeutics, a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today...
2 Gene-Editing Stocks to Have on Your Radar Right Now
They only have preclinical candidates for now. But these biotechs could have game-changing gene-editing therapies.
Verve Therapeutics to Participate in the Chardan Virtual 5th Annual Genetic Medicines Conference
CAMBRIDGE, Mass., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Verve Therapeutics, a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, toda...
Verve Therapeutics' Gene-Editing Therapy Shows Encouraging Preclinical Action In Cardiovascular Disease
Verve Therapeutics Inc (NASDAQ: VERV) has reported new preclinical data from 36 non-human primates (NHPs) with its lead candidate, VERVE-101. VERVE-101 is a potential single-course gene-editing treatmen...
Verve Therapeutics Announces Business and Program Highlights and Reports Second Quarter 2021 Financial Results
New Preclinical Base Editing Durability Data and Proprietary GalNAc-targeted Lipid Nanoparticle Delivery Technology Data to be Presented at TIDES in September 2021
Verve Therapeutics Gets Off to a Fast Start
The dictionary describes the word “verve” as having energy, or vitality. It seems appropriate, then, that shares of biotech startup Verve Therapeutics, Inc. ( VERV , Financial) are up nearly $170% to $5...
Ignoring Monday's 2 Big Nasdaq Winners Could Cost You Serious Money
Find out why these stocks are climbing higher.
Verve Therapeutics Announces Pricing of Initial Public Offering
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Verve Therapeutics, a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the pr...
Verve Therapeutics IPO Registration Document (S-1)
Verve Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.
Using CRISPR to lower cholesterol levels in monkeys
A team of researchers from Verve Therapeutics and the Perelman School of Medicine at the University of Pennsylvania has developed a CRISPR gene-editing technique that lowered the levels of cholesterol i...
Verve Therapeutics Announces Nature Publication Highlighting its Use of Base Editing to Potently and Durably Lower Bl...
VerveTx Announces Nature Publication Highlighting its Use of Base Editing to Potently and Durably Lower Blood PCSK9 and LDL-C in Non-Human Primates